文献速递肾小球疾病

多中心盲法临床前随机对照试验:Jak1/2抑制在增殖性狼疮肾炎MRL/MpJ-Faslpr小鼠中预测低效应量

A multicenter blinded preclinical randomized controlled trial on Jak1/2 inhibition in MRL/MpJ-Faslpr mice with proliferative lupus nephritis predicts low effect size.
PubMed 文献 · Kidney Int · 2021-02-16

该研究在西班牙和德国四个学术中心开展首个肾脏领域多中心临床前随机对照试验(pRCT),将13-14周龄雌性MRL/MpJ-Faslpr小鼠随机分配至口服巴瑞替尼或溶媒治疗4周,由独立第五中心进行盲法组织学分析。结果显示巴瑞替尼未显著影响蛋白尿、组织学活动/慢性指数或肾小球滤过率,但显著改善血浆自身抗体水平和淋巴结肿大,提示多中心pRCT可克服单中心偏倚但增加变异性并降低效应量,预测巴瑞替尼在异质性人群中对人狼疮肾炎效应量低。

要点

  • 巴瑞替尼未显著改善蛋白尿、组织学活动/慢性指数或肾小球滤过率。
  • 巴瑞替尼显著改善血浆自身抗体水平和淋巴结肿大。
  • 多中心pRCT可克服单中心偏倚但增加变异性并降低效应量。

核心结论

  • 多中心临床前随机对照试验可克服单中心偏倚,但代价是增加变异性并降低效应量。
  • 该试验预测巴瑞替尼在异质性研究人群中对人狼疮肾炎的效应量低。

研究设计与样本

  • 首个肾脏领域多中心临床前随机对照试验,在西班牙和德国四个学术中心开展。
  • 合格MRL/MpJ-Faslpr小鼠(雌性,13-14周龄,应激评分小于2且无可见肿瘤或感染迹象)等量随机分配至口服巴瑞替尼或溶媒治疗4周。
  • 由独立第五中心进行盲法中心组织学分析,主要终点为尿蛋白/肌酐比值。

主要发现

  • 巴瑞替尼治疗未显著影响蛋白尿、组织学活动与慢性标志物或肾小球滤过率。
  • 巴瑞替尼治疗显著改善血浆自身抗体水平和淋巴结肿大。
  • 不同中心间存在数据异质性,部分与不同站点饲养的MRL/MpJ-Faslpr小鼠表型差异有关,模拟了狼疮试验中患者表型多样性。

临床怎么用

  • 提示在将临床前结果转化至人狼疮肾炎试验时,需考虑多中心异质性对效应量的影响。
  • 巴瑞替尼在异质性人群中对狼疮肾炎的预期效应量可能较低,临床试验设计应充分考虑。

局限性

  • 多中心pRCT增加数据变异性并降低效应量,可能影响结果解读。
  • 不同中心饲养的小鼠存在表型差异,导致数据异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Data reproducibility and single-center bias are concerns in preclinical research and compromise translation from animal to human. Multicenter preclinical randomized controlled trials (pRCT) may reduce the gap between experimental studies and RCT and improve the predictability of results, for example Jak1/2 inhibition in lupus nephritis. To evaluate this, we conducted the first pRCT in the kidney domain at two Spanish and two German academic sites. Eligible MRL/MpJ-Faslpr mice (female, age13-14 weeks, stress scores of less than two and no visible tumor or signs of infection) were equally randomized to either oral treatment with the Jak1/2 inhibitor baricitinib or vehicle for four weeks. Central blinded histology analysis was performed at an independent fifth site. The primary endpoint was the urinary protein/creatinine ratio. Baricitinib treatment did not significantly affect proteinuria, histological markers of activity and chronicity, or the glomerular filtration rate but significantly improved plasma autoantibody levels and lymphadenopathy. Data heterogeneity was noted across the different centers referring in part to phenotype differences between MRL/MpJ-Faslpr mice bred at different sites, mimicking well patient phenotype diversity in lupus trials. Multicenter pRCT can overcome single-center bias at the cost of increasing variability and reducing effect size. Thus, our pRCT predicts a low effect size of baricitinib treatment on human lupus nephritis in heterogeneous study populations.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Lei Y, Sehnert B, Voll RE, et al. A multicenter blinded preclinical randomized controlled trial on Jak1/2 inhibition in MRL/MpJ-Faslpr mice with proliferative lupus nephritis predicts low effect size. Kidney Int. 2021. PMID: 33607177. doi:10.1016/j.kint.2021.01.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。